期刊文献+

瑞舒伐他汀对高血压病合并高脂血症患者超敏C-反应蛋白的影响 被引量:8

下载PDF
导出
摘要 目的探讨瑞舒伐他汀对高血压合并高脂血症患者超敏C-反应蛋白(hsCRP)的影响。方法72例高血压病合并高脂血症患者在常规降压治疗基础上睡前加服瑞舒伐他汀10 mg,1次.d-1;80例单纯高脂血症患者睡前服用瑞舒伐他汀10 mg,1次.d-1;另外选择年龄、性别等相匹配60例正常体检者作为对照组。3组治疗时间均为12周,观察3组研究对象治疗前后血压、血脂、hsCRP等指标的变化。结果治疗前高血压病合并高脂血症组患者的血压和血脂明显高于对照组,经降压和降脂治疗后血压与血脂均显著下降(P<0.05)。瑞舒伐他汀治疗前高血压病合并高脂血症组和单纯高脂血症组hsCRP的水平均明显高于对照组(P<0.01),治疗后hsCRP水平显著下降(P<0.01)。结论瑞舒伐他汀可明显降低高血压病合并高脂血症患者hsCRP水平,从而可能改善高血压病合并高脂血症患者的炎症状态,减缓动脉粥样硬化的形成。
出处 《现代医学》 2009年第6期426-428,共3页 Modern Medical Journal
  • 相关文献

参考文献7

  • 1赵水平.他汀类药物非降脂作用研究现状[J].医学临床研究,2004,21(1):1-2. 被引量:40
  • 2Sesso B. The patients with high level of serum CRP have a higher risk incidence with EH [ J ]. JAMA, 2003, 290: 2945-2950.
  • 3Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein [J]. J Clin Hypertens ( Greenwich ) , 2008,10 (9) :677-683.
  • 4Ridker P M, Silvertown J D. Inflammation, C-reactive protein, and atherothrombosis [ J ]. J Periodontol, 2008,79 ( 8 Suppl ) : 1544-1551.
  • 5Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen : results from the pravastatin or atrovastatin evaluation and infection therapy-thromilysis in myocardial infarction 22 (PROVE IT-TIM 22) trail [ J ]. Am J Med,2005,118 Supple 12A : 28- 35.
  • 6石先辉,贾如意.阿托伐他汀在急性冠状动脉综合征中的抗炎作用及临床应用[J].医学综述,2008,14(12):1888-1890. 被引量:25
  • 7Ridker P M, Danielson E, Fonseca F A,et al. Rosuvastation to prevent vascular events in men and women with elevated C-reactive protein[J]. N Eng J Med ,2008,359( 21 ) :2195-2207.

二级参考文献19

共引文献58

同被引文献67

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 2刘晓梅,高丹丹.不同剂量辛伐他汀治疗冠心病的临床观察[J].医学信息(西安上半月),2006,19(11):2025-2026. 被引量:3
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 4范建高,蔡晓波.他汀类药物肝脏安全性问题[J].中华心血管病杂志,2007,35(6):589-592. 被引量:27
  • 5Rosendo AB, Lima LO, Dal-Pizzol F, et al. Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals[J]. Inflammation, 2010,33 (4): 244-250.
  • 6Ridker PM, Danielson E, Fonseca F, et al. Rosuvastatin to pre- vent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008,359(21): 2195-2207.
  • 7Manisty C, Mayet J, Tapp RJ, et al. Atorvastatin treatment is associated with less augmentation of the carotid pressure wave- form in hypertension: a substudy of the Anglo-Scandinavian cardi- ac outcome trial (ASCOT) [J]. Hypertension, 2009,54 (5) : 1009- 1013.
  • 8Muir RL. Peripheral arterialdisease: pathophysiology, risk fac- tors, diagnosis, treatment, and prevention [J]. J Vasc Nurs, 2009,27(2) : 26-30.
  • 9Li X, Luo Y, Xu Y, et al. Relationship of ankle-brachial index with all-cause mortality and cardiovascular mortality after a 3-year follow-up: the China ankle-hrachial index cohort study[J]. J Hum Hypertens, 2010,24(2): 111-116.
  • 10Weatherley BD,Nelson JJ,Heiss G,et al.The association of the anklebrachial index with incident coronary heart disease:the Atherosclerosis Risk In Communities (ARIC) study, 1987-2001[J].BMC Cardiovasc Disord,2007,7:3.

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部